Unprecedented developments in genomics and molecular biology today offer a plethora of new drug targets. The method by which a drug is delivered to these targets can have a significant impact on its efficacy. Some drugs have an optimum concentration spectrum within which maximum benefit is derived, and concentrations out of this range can be toxic or produce no therapeutic benefit at all. This, with the very slow progress in the efficacy of the treatment of severe diseases, has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues. It is estimated that close to 50% of the newly developed drugs cannot be taken orally.
This increase in numbers for the NDDS market is to be driven by the increased requirement for improving the efficacy, safety and bio-recognition of drugs for disease-specific sites within the body, and also the need to improve the comfort levels of patient who are the users of the drugs.
These requirements have led to the need for controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, bio-recognition, and efficacy of drugs, in turn leading to the birth of drug delivery systems. The introduction of novel delivery systems to an existing molecule should significantly improve its safety, efficacy, and patient compliance. Most of the innovator companies have a parallel research pipeline for biopharmaceuticals and concentrate also on innovative delivery platforms.
The market has been segmented by route of administration (oral, injectable, pulmonary, transdermal and others) and by geography (North America, Europe, Asia-Pacific and the Rest of the World).
This Report Offers:
Market definition for the global NDDS market along with identification of key drivers and restraints for the market.
Market analysis for the NDDS market, with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their share of markets.
Identification and analysis of the macro and micro factors that affect the NDDS market on both global and regional scale.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Market Overview
5.3 New Developments
5.4 PorterFive Forces
5.4.1 Bargaining Power of Suppliers
5.4.2 Bargaining Power of Consumers
5.4.3 Threat of New Entrants
5.4.4 Threat of Substitute Products and Services
5.4.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis
6.1 Market Drivers
6.1.1 Increase in individual therapy
6.1.2 Requirement of controlled release of drugs
6.1.3 Increasing understanding of drug metabolism per individual
6.2 Market Restraints
6.2.2 Product Recalls
6.2.3 Stringent Regulatory Guidelines
6.2.4 Stability issues
6.3.1 Patent Expiries of Blockbuster Drugs
6.4.1 High cost of development
7. Novel Drug Delivery Devices Market Segmentation
7.1 By Route of Administration
7.1.1 Oral Drug Delivery Systems
7.1.2 Injectable Drug Delivery Systems
7.1.3 Pulmonary Drug Delivery Systems
7.1.4 Transdermal Drug Delivery Systems
7.2 By Geography
7.2.1 North America
188.8.131.52 United States
184.108.40.206 Spain & Portugal
220.127.116.11 United Kingdom
18.104.22.168 Australia & New Zealand
22.214.171.124 South Korea
7.2.4 Rest of the World
8. Upcoming Drug Delivery Technologies
8.4 Micro and Nano Emulsions
8.6 Vesicular systems
9. Competitive Landscape
9.1 Mergers & Acquisitions
9.2 Agreements, Collaborations & Partnerships
9.3 New Product Launches
10. Company Profiles
10.1 3M Company
10.2 Abbott Laboratories
10.3 Amgen Inc.
10.4 AstraZeneca PLC
10.5 Bausch & Lomb
10.6 Baxter International Inc.
10.7 Bayer Healthcare Pharmaceuticals
10.8 Boehringer Ingelheim
10.9 Boston Scientific
10.10 Bristol-Myers Squibb
10.11 Celgene Corporation
10.12 Cephalon, Inc.
10.13 Genentech Inc.
10.14 Generex Biotechnology Corporation
10.15 Genzyme Corporation
10.16 GlaxoSmithKline PLC
10.17 Johnson & Johnson
10.18 Mannkind Corporation
10.19 Merck & Co.
10.20 Mylan Laboratories Inc.
10.21 Novartis AG
10.22 Pfizer Inc.
10.23 Roche Holding AG
10.24 Sanofi SA
10.25 Teva Pharmaceutical Industries Ltd.
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market